352 related articles for article (PubMed ID: 31786260)
41. An overview of disease models for NLRP3 inflammasome over-activation.
Zhang H; Zahid A; Ismail H; Tang Y; Jin T; Tao J
Expert Opin Drug Discov; 2021 Apr; 16(4):429-446. PubMed ID: 33131335
[No Abstract] [Full Text] [Related]
42. Advances in the molecular mechanisms of NLRP3 inflammasome activators and inactivators.
Liu D; Zeng X; Li X; Cui C; Hou R; Guo Z; Mehta JL; Wang X
Biochem Pharmacol; 2020 May; 175():113863. PubMed ID: 32081791
[TBL] [Abstract][Full Text] [Related]
43. Melatonin-mediated mitophagy protects against early brain injury after subarachnoid hemorrhage through inhibition of NLRP3 inflammasome activation.
Cao S; Shrestha S; Li J; Yu X; Chen J; Yan F; Ying G; Gu C; Wang L; Chen G
Sci Rep; 2017 May; 7(1):2417. PubMed ID: 28546552
[TBL] [Abstract][Full Text] [Related]
44. NLRP3 inflammasome: A likely target for the treatment of allergic diseases.
Xiao Y; Xu W; Su W
Clin Exp Allergy; 2018 Sep; 48(9):1080-1091. PubMed ID: 29900602
[TBL] [Abstract][Full Text] [Related]
45. [Regulation of the NLRP3 inflammasome].
Groslambert M; Py BF
Med Sci (Paris); 2018 Jan; 34(1):47-53. PubMed ID: 29384096
[TBL] [Abstract][Full Text] [Related]
46. Ameliorative effects of echinacoside against spinal cord injury via inhibiting NLRP3 inflammasome signaling pathway.
Gao S; Xu T; Guo H; Deng Q; Xun C; Liang W; Sheng W
Life Sci; 2019 Nov; 237():116978. PubMed ID: 31644893
[TBL] [Abstract][Full Text] [Related]
47. Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases.
An N; Gao Y; Si Z; Zhang H; Wang L; Tian C; Yuan M; Yang X; Li X; Shang H; Xiong X; Xing Y
Front Immunol; 2019; 10():1592. PubMed ID: 31354731
[TBL] [Abstract][Full Text] [Related]
48. NLRP3 Inflammasome in Cardioprotective Signaling.
Zuurbier CJ
J Cardiovasc Pharmacol; 2019 Oct; 74(4):271-275. PubMed ID: 31356546
[TBL] [Abstract][Full Text] [Related]
49. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.
Marchetti C; Swartzwelter B; Gamboni F; Neff CP; Richter K; Azam T; Carta S; Tengesdal I; Nemkov T; D'Alessandro A; Henry C; Jones GS; Goodrich SA; St Laurent JP; Jones TM; Scribner CL; Barrow RB; Altman RD; Skouras DB; Gattorno M; Grau V; Janciauskiene S; Rubartelli A; Joosten LAB; Dinarello CA
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1530-E1539. PubMed ID: 29378952
[TBL] [Abstract][Full Text] [Related]
50. Negative regulation of NLRP3 inflammasome by SIRT1 in vascular endothelial cells.
Li Y; Yang X; He Y; Wang W; Zhang J; Zhang W; Jing T; Wang B; Lin R
Immunobiology; 2017 Mar; 222(3):552-561. PubMed ID: 27908642
[TBL] [Abstract][Full Text] [Related]
51. Cyclooxygenase-2 regulates NLRP3 inflammasome-derived IL-1β production.
Hua KF; Chou JC; Ka SM; Tasi YL; Chen A; Wu SH; Chiu HW; Wong WT; Wang YF; Tsai CL; Ho CL; Lin CH
J Cell Physiol; 2015 Apr; 230(4):863-74. PubMed ID: 25294243
[TBL] [Abstract][Full Text] [Related]
52. New evidence of connections between increased O-GlcNAcylation and inflammasome in the oral mucosa of patients with oral lichen planus.
Thi Do T; Phoomak C; Champattanachai V; Silsirivanit A; Chaiyarit P
Clin Exp Immunol; 2018 Apr; 192(1):129-137. PubMed ID: 29247492
[TBL] [Abstract][Full Text] [Related]
53. Calcium-sensing receptor activates the NLRP3 inflammasome in LS14 preadipocytes mediated by ERK1/2 signaling.
D'Espessailles A; Mora YA; Fuentes C; Cifuentes M
J Cell Physiol; 2018 Aug; 233(8):6232-6240. PubMed ID: 29345311
[TBL] [Abstract][Full Text] [Related]
54. Gallic and butyric acids modulated NLRP3 inflammasome markers in a co-culture model of intestinal inflammation.
Luzardo-Ocampo I; Loarca-Piña G; Gonzalez de Mejia E
Food Chem Toxicol; 2020 Dec; 146():111835. PubMed ID: 33130239
[TBL] [Abstract][Full Text] [Related]
55. Nuclear Factor E2-Related Factor-2 Negatively Regulates NLRP3 Inflammasome Activity by Inhibiting Reactive Oxygen Species-Induced NLRP3 Priming.
Liu X; Zhang X; Ding Y; Zhou W; Tao L; Lu P; Wang Y; Hu R
Antioxid Redox Signal; 2017 Jan; 26(1):28-43. PubMed ID: 27308893
[TBL] [Abstract][Full Text] [Related]
56. Vascular endothelial cells senescence is associated with NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation via reactive oxygen species (ROS)/thioredoxin-interacting protein (TXNIP) pathway.
Yin Y; Zhou Z; Liu W; Chang Q; Sun G; Dai Y
Int J Biochem Cell Biol; 2017 Mar; 84():22-34. PubMed ID: 28064010
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of novel selective NLRP3 inhibitors in human and murine retinal pigment epithelial cells.
Wang L; Schmidt S; Larsen PP; Meyer JH; Roush WR; Latz E; Holz FG; Krohne TU
J Mol Med (Berl); 2019 Apr; 97(4):523-532. PubMed ID: 30739141
[TBL] [Abstract][Full Text] [Related]
58. Role of NLRP3 Inflammasome in Cardiac Inflammation and Remodeling after Myocardial Infarction.
Takahashi M
Biol Pharm Bull; 2019; 42(4):518-523. PubMed ID: 30930410
[TBL] [Abstract][Full Text] [Related]
59. Human immunodeficiency virus Type-1 single-stranded RNA activates the NLRP3 inflammasome and impairs autophagic clearance of damaged mitochondria in human microglia.
Rawat P; Teodorof-Diedrich C; Spector SA
Glia; 2019 May; 67(5):802-824. PubMed ID: 30582668
[TBL] [Abstract][Full Text] [Related]
60. Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential.
Su M; Wang W; Liu F; Li H
Curr Med Chem; 2021; 28(3):569-582. PubMed ID: 31971103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
